Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
May 20 2016 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M.
Kaye, M.D., has been appointed to the company’s Board of Directors.
Dr. Kaye is the Interim Chief Executive Officer and Senior Vice
President, Chief Medical Officer of Sarepta Therapeutics.
Dr. Kaye joins the Cytokinetics Board of
Directors with substantial industry experience in rare diseases
including neurological conditions. He has served as Interim Chief
Executive Officer of Sarepta since 2015 and as the SVP, Chief
Medical Officer since 2011. Prior to joining Sarepta, Dr. Kaye was
employed by Genzyme Corporation for ten years, holding various
senior management positions, the most recent of which was Group
Vice President of Clinical Development, in which he supervised
clinical research in lysosomal storage disease programs and genetic
neurological disorders. Previously, Dr. Kaye served as Chief of
Biochemical Genetics at Children’s Hospital of Philadelphia and
Associate Professor of Neurology and Pediatrics at the University
Of Pennsylvania School Of Medicine. Dr. Kaye serves as a
Neurological Consultant at the Children's Hospital of Boston and is
on the editorial boards of a number of medical journals. He is also
a member of several scientific advisory boards, including United
Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation,
CureCMD, CureDuchenne and Prize4Life. Dr. Kaye received his medical
education and pediatric training at Loyola University Stritch
School of Medicine and University Hospital, child neurology
training at Boston City Hospital, Boston University, and completed
his training as a neurochemical research fellow at Bedford VA
Hospital, Boston University.
“We are pleased to welcome Ed to our Board. His
expertise in rare neuromuscular diseases is highly relevant as we
advance our clinical programs in ALS and SMA into late-stage
development,” said Robert I. Blum, Cytokinetics’ President and
Chief Executive Officer. “Ed has overseen many clinical research
and development programs, and we look forward to the benefit of his
industry-leading experience.”
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal muscle troponin activator, for
the potential treatment of ALS. Tirasemtiv has been
granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan
medicinal product designation by the European Medicines
Agency for the potential treatment of
ALS. Cytokinetics retains the right to develop and
commercialize tirasemtiv. Cytokinetics is
collaborating with Amgen Inc. to develop omecamtiv
mecarbil, a novel cardiac muscle activator, for the potential
treatment of heart failure. Cytokinetics is collaborating
with Astellas Pharma Inc. to develop CK-2127107, a fast
skeletal muscle activator, for the potential treatment of spinal
muscular atrophy and chronic obstructive pulmonary
disease. Amgen holds an exclusive license worldwide to
develop and commercialize omecamtiv mecarbil and Astellas
holds an exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject
to Cytokinetics' specified development and
commercialization participation rights. For additional information
about Cytokinetics, visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"). Cytokinetics disclaims any intent or obligation to
update these forward-looking statements, and claims the protection
of the Act's safe harbor for forward-looking statements. Examples
of such statements include, but are not limited to, statements
relating to the potential advancement of its drug candidates in
late-stage clinical trials. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024